Domov › Rak dojke › Arizona › Phoenix
Klinične študije za Rak dojke v Phoenix, AZ
25 študij za Rak dojke išče udeležence na lokacijah v Phoenix in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.
Uradno besedilo študije (angleško)
Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci
- Cancer Center at Saint Joseph's, Phoenix
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
Vključevanje udeležencevFaza 2
- Mayo Clinic Hospital, Phoenix
PRE-ISPY Phase I/II Oncology Platform Program
Vključevanje udeležencevFaza 1/2
- Mayo Clinic Comprehensive Cancer Center, Phoenix
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Vključevanje udeležencevFaza 3
- Mayo Clinic Cancer Center ( Site 0034), Phoenix
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
Vključevanje udeležencevFaza 3
- Ironwood Cancer & Research Centers, Phoenix
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
Vključevanje udeležencevFaza 2
- Mayo Clinic Building-Phoenix, Phoenix
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Vključevanje udeležencev
- Mayo Clinic Arizona, Phoenix
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Vključevanje udeležencevFaza 3
- Mayo Clinic in Arizona - Phoenix, Phoenix
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
Vključevanje udeležencevFaza 2
- Mayo Clinic in Arizona - Phoenix, Phoenix
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Vključevanje udeležencevFaza 3
- Banner University Medical Center - Phoenix Campus (Banner Good Samaritan Medical Center), Phoenix
Breast Cancer, Reasoning, and Activity Intervention
Vključevanje udeležencev
- Mayo Clinic in Arizona, Phoenix
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Vključevanje udeležencevFaza 3
- The Dignity Health Cancer Institute, Phoenix
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Vključevanje udeležencevFaza 3
- Cancer Center at Saint Joseph's, Phoenix
- Mayo Clinic Hospital in Arizona, Phoenix
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
Vključevanje udeležencevFaza 3
- Mayo Clinic-Comprehensive Cancer Center-Breast Clinic, Phoenix
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Vključevanje udeležencevFaza 3
- Mayo Clinic Hospital in Arizona, Phoenix
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Vključevanje udeležencevFaza 1/2
- USOR HonorHealth, Phoenix
E-Mindfulness Approaches for Living After Breast Cancer
Vključevanje udeležencevFaza 3
- Mayo Clinic Hospital in Arizona, Phoenix
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Vključevanje udeležencevFaza 1/2
- Mayo Clinic Comprehensive Cancer Center, Phoenix
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Vključevanje udeležencevFaza 3
- Ironwood Cancer & Research Centers, Phoenix
The RolE of Prolonged Nightly faSTing to Improve Sleep and cOgnition in bREast Cancer Survivors
Vključevanje udeležencev
- Arizona State University, Phoenix
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Vključevanje udeležencevFaza 3
- Cancer Center at Saint Joseph's, Phoenix
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Vključevanje udeležencevFaza 1/2
- Mayo Clinic, Phoenix
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Vključevanje udeležencevOpazovalna študija
- Cancer Center at Saint Joseph's, Phoenix
Clinical Validation of Early Detection Blood Test for Universal Large-scale Breast Cancer Screening
Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci
- Vincere Cancer Center, Phoenix
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Vključevanje udeležencevOpazovalna študija
- Arizona Oncology Associates, PC, Phoenix
Študije za Rak dojke v drugih mestih
- New York City, NY134 študij
- Houston, TX126 študij
- Boston, MA111 študij
- Nashville, TN80 študij
- Los Angeles, CA72 študij
- Edison, NJ68 študij
- St. Louis, MO64 študij
- Durham, NC63 študij
- Queens, NY63 študij
- Chicago, IL58 študij
- Philadelphia, PA56 študij
- Dallas, TX55 študij
Druge študije v Phoenix
- Kolorektalni rak25 študij
- Debelost22 študij
- Nemalicelični pljučni rak20 študij
- Metastatski rak20 študij
- Srčno popuščanje18 študij
- Rak prostate17 študij
- Rak (vse vrste)17 študij
- Množni mielom16 študij
- Rak trebušne slinavke16 študij
- Srčno-žilne bolezni16 študij
- Alzheimerjeva bolezen15 študij
- Prekomerna telesna teža15 študij
Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.